95 related articles for article (PubMed ID: 22450752)
21. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
22. Role of 14-3-3σ in resistance to cisplatin in non-small cell lung cancer cells.
Cetintas VB; Tetik A; Cok G; Kucukaslan AS; Kosova B; Gunduz C; Veral A; Eroglu Z
Cell Biol Int; 2013 Jan; 37(1):78-86. PubMed ID: 23339090
[TBL] [Abstract][Full Text] [Related]
23. Effects of polyphyllin I on growth inhibition of human non-small lung cancer cells and in xenograft.
Kong M; Fan J; Dong A; Cheng H; Xu R
Acta Biochim Biophys Sin (Shanghai); 2010 Nov; 42(11):827-33. PubMed ID: 20978038
[TBL] [Abstract][Full Text] [Related]
24. Tumor-associated antigen L6 and the invasion of human lung cancer cells.
Kao YR; Shih JY; Wen WC; Ko YP; Chen BM; Chan YL; Chu YW; Yang PC; Wu CW; Roffler SR
Clin Cancer Res; 2003 Jul; 9(7):2807-16. PubMed ID: 12855661
[TBL] [Abstract][Full Text] [Related]
25. [Treatment of the unresectable non small cell lung carcinoma].
Spásová I
Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
[TBL] [Abstract][Full Text] [Related]
26. CCL21 promotes the migration and adhesion of highly lymph node metastatic human non-small cell lung cancer Lu-99 in vitro.
Koizumi K; Kozawa Y; Ohashi Y; Nakamura ES; Aozuka Y; Sakurai H; Ichiki K; Doki Y; Misaki T; Saiki I
Oncol Rep; 2007 Jun; 17(6):1511-6. PubMed ID: 17487412
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.
Treszl A; Schally AV; Seitz S; Szalontay L; Rick FG; Szepeshazi K; Halmos G
Peptides; 2009 Sep; 30(9):1643-50. PubMed ID: 19524629
[TBL] [Abstract][Full Text] [Related]
28. Effects of collagen iv on cisplatin-induced apoptosis of non-small cell lung cancer cells.
Su C; Su B; Tang L; Zhao Y; Zhou C
Cancer Invest; 2007; 25(7):542-9. PubMed ID: 17952737
[TBL] [Abstract][Full Text] [Related]
29. Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells.
Zhang J; Ren H; Yuan P; Lang W; Zhang L; Mao L
Cancer Res; 2006 Jan; 66(1):18-23. PubMed ID: 16397209
[TBL] [Abstract][Full Text] [Related]
30. Prediction of chemotherapeutic effect on postoperative recurrence by in vitro anticancer drug sensitivity testing in non-small cell lung cancer patients.
Higashiyama M; Oda K; Okami J; Maeda J; Kodama K; Imamura F; Minamikawa K; Takano T; Kobayashi H
Lung Cancer; 2010 Jun; 68(3):472-7. PubMed ID: 19660825
[TBL] [Abstract][Full Text] [Related]
31. Tyroservatide therapy for tumor growth, invasion and metastasis of Lewis lung carcinoma and human lung carcinoma A549.
Zheng M; Lu R; Che X; Li J; Zhou C; Wang L; Xu Q; Cao H; Li Q; Yao Z
Oncology; 2006; 70(6):418-26. PubMed ID: 17245103
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2.
Xu G; Yu H; Shi X; Sun L; Zhou Q; Zheng D; Shi H; Li N; Zhang X; Shao G
BMC Pulm Med; 2014 Nov; 14():174. PubMed ID: 25380840
[TBL] [Abstract][Full Text] [Related]
33. Sub-toxic cisplatin mediates anoikis resistance through hydrogen peroxide-induced caveolin-1 up-regulation in non-small cell lung cancer cells.
Songserm T; Pongrakhananon V; Chanvorachote P
Anticancer Res; 2012 May; 32(5):1659-69. PubMed ID: 22593444
[TBL] [Abstract][Full Text] [Related]
34. [Effects of protein kinase C inhibitor,chelerythrine chloride,on drug-sensitivity of NSCLC cell lines].
Gao Z; Tang L; Su B; Sha H; Han B
Zhongguo Fei Ai Za Zhi; 2007 Dec; 10(6):455-60. PubMed ID: 21129299
[TBL] [Abstract][Full Text] [Related]
35. Circulating tumor cells from a 4-dimensional lung cancer model are resistant to cisplatin.
Vishnoi M; Mishra DK; Thrall MJ; Kurie JM; Kim MP
J Thorac Cardiovasc Surg; 2014 Sep; 148(3):1056-63; discussion 1063-4. PubMed ID: 25129597
[TBL] [Abstract][Full Text] [Related]
36. Discovery of 2-[2-(5-nitrofuran-2-yl)vinyl]quinoline derivatives as a novel type of antimetastatic agents.
Tseng CH; Tzeng CC; Chiu CC; Hsu CY; Chou CK; Chen YL
Bioorg Med Chem; 2015 Jan; 23(1):141-8. PubMed ID: 25467291
[TBL] [Abstract][Full Text] [Related]
37. Acacetin enhances the therapeutic efficacy of doxorubicin in non-small-cell lung carcinoma cells.
Punia R; Raina K; Agarwal R; Singh RP
PLoS One; 2017; 12(8):e0182870. PubMed ID: 28859099
[TBL] [Abstract][Full Text] [Related]
38. In vivo selection for spine-derived highly metastatic lung cancer cells is associated with increased migration, inflammation and decreased adhesion.
Cai X; Luo J; Yang X; Deng H; Zhang J; Li S; Wei H; Yang C; Xu L; Jin R; Li Z; Zhou W; Ding J; Chu J; Jia L; Jia Q; Tan C; Liu M; Xiao J
Oncotarget; 2015 Sep; 6(26):22905-17. PubMed ID: 26090868
[TBL] [Abstract][Full Text] [Related]
39. Differential effects of sevoflurane on the metastatic potential and chemosensitivity of non-small-cell lung adenocarcinoma and renal cell carcinoma in vitro.
Ciechanowicz S; Zhao H; Chen Q; Cui J; Mi E; Mi E; Lian Q; Ma D
Br J Anaesth; 2018 Feb; 120(2):368-375. PubMed ID: 29406185
[TBL] [Abstract][Full Text] [Related]
40. X-ray irradiation altered chemosensitivity of a p53-null non-small cell lung cancer cell line.
Tsutsumi K; Yasuda M; Nishioka T
Cell Struct Funct; 2006; 31(2):47-52. PubMed ID: 16951535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
